Advertisement
Canada markets closed
  • S&P/TSX

    22,468.16
    +2.79 (+0.01%)
     
  • S&P 500

    5,321.41
    +13.28 (+0.25%)
     
  • DOW

    39,872.99
    +66.22 (+0.17%)
     
  • CAD/USD

    0.7331
    -0.0010 (-0.14%)
     
  • CRUDE OIL

    79.06
    -0.74 (-0.93%)
     
  • Bitcoin CAD

    95,178.63
    +159.55 (+0.17%)
     
  • CMC Crypto 200

    1,515.10
    +26.56 (+1.78%)
     
  • GOLD FUTURES

    2,425.20
    -0.70 (-0.03%)
     
  • RUSSELL 2000

    2,098.36
    -4.14 (-0.20%)
     
  • 10-Yr Bond

    4.4140
    -0.0230 (-0.52%)
     
  • NASDAQ futures

    18,798.75
    +35.75 (+0.19%)
     
  • VOLATILITY

    11.86
    -0.29 (-2.39%)
     
  • FTSE

    8,416.45
    -7.75 (-0.09%)
     
  • NIKKEI 225

    38,946.93
    -122.75 (-0.31%)
     
  • CAD/EUR

    0.6751
    -0.0005 (-0.07%)
     

Amgen surges over confidence in early obesity drug results

Shares of Amgen (AMGN) are jumping Friday morning after the company showed confidence in early results from a GLP-1 weight-loss drug that is in development to treat obesity. The pharmaceutical giant beat first-quarter revenue estimates while reporting a loss of $113 million.

Yahoo Finance Senior Health Reporter Anjalee Khemlani joins The Morning Brief to break down the latest developments from Amgen and its outlook on use cases for the drug in question, MariTide.

For more expert insight and the latest market action, click here to watch this full episode of Morning Brief.

This post was written by Nicholas Jacobino